TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04945421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: (IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: (IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
Study: NCT05809661

Intervention type: BEHAVIORAL
Intervention: implementation of the nurse navigation program
Description: Adult patients with intestinal stoma were contacted continuously for 6 months.
Study: NCT04607655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1211
Description: GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1211
Description: GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered as inhalation once a day
Study: NCT05753865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX2011
Description: IV infusion, 260 mg/m\^2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel for injection (albumin-bound)
Description: IV infusion, 260 mg/m\^2
Study: NCT04532723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExoAtlet II
Description: ExoAtlet II is the second version of an exoskeleton that ExoAtlet has manufactured
Study: NCT04896333

Intervention type: OTHER
Intervention: Interaction and exposure with the Robot EBO
Description: The participants will interact with the Robot EBO. The robot will be control by an operator that will conduct a dialogue. The dialogue will include questions related to the social, leisure, activities of daily living and informative areas.
Study: NCT04728308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Before closing the skin incision,Infiltration of 20ml of 0.5% bupivacaine around incision site will be done in the patients of experimental group and 20 ml of distill water will be infiltrated in the pateints of the placebo group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacain
Description: Before closing the skin incision,Infiltration of 20ml of 0.5% bupivacaine around incision site will be done in the patients of experimental group and 20 ml of distill water will be infiltrated in the pateints of the placebo group
Study: NCT06424730

Intervention type: OTHER
Group type: OTHER
Intervention: Feasibility Interview
Description: One audio-recorded interview with the participants lasting about 30-minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team Based Equity Conscious Telemedicine Hypertension Intervention
Description: Will provide blood pressure monitor connected to a telehealth application. Patients will be asked to measure home blood pressure once daily. Will intensify medications as needed based on blood pressure measurement. Trained nurses or pharmacists will provide 4 self-management telephone calls (up to 30 minutes per call) to patients to address hypertension knowledge, medication adherence, healthy eating, physical activity, weight management, stress management, tobacco and alcohol use, and sleep apnea (with referrals if needed). Will support needs relevant in blood pressure control using locally available resources via community health worker and social workers.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Usual clinic based hypertension care using routinely available clinic services including community health worker/social worker. Clinicians can offer self-management support (e.g., dietician referral) or recommend a home blood pressure monitor. These activities mirror current primary care practice.
Study: NCT05377281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Tissue Implantation
Description: At the time participants are receiving the standard of care deep brain stimulation (DBS) surgery, a standard incision on the lateral aspect near the ankle is made, the sural nerve is identified, an about 3 cm biopsy of the sural nerve is obtained and the incision is closed. From the biopsied section, the epinerium is removed, fascicles are cut, and (\~5 pieces per side; \~ 5mm length x 1.5 mm diameter: approximately 10 cubic millimeters) implanted bilaterally into the substantia nigra.
Study: NCT05698134

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ROTEM
Description: ROTEM is a commercially available whole blood Viscoelastic-Haemostatic Assay(VHA) point-of-care, global and dynamic haemostasis assessment tests that measures the viscoelastic changes occurring during the haemostatic process. They provide real-time, comprehensive reflection of the interaction between plasma, blood cells and platelets. It display hypo or hyper-coagulable features in patients with cirrhosis. It is widely used prior to cardiac, obstetric, trauma and liver transplant surgery to assess and correct for coagulation defects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study: NCT05709990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin Succinate 5 MG Oral Tablet [Vesicare]
Description: These patients will receive solifenacin 5-10 MG daily (combined with standard urotherapy) for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: These patients will receive high dose vitamin D supplementation (more than 2000IU daily) (combined with standard urotherapy) for 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard urotherapy
Description: These patients will receive standard urotherapyfor 8 weeks.
Study: NCT06096480

Intervention type: PROCEDURE
Intervention: gabapentin + bilateral spine erector block
Description: preoperative, ultrasound-guided, bilateral ESP block (administration of a local anesthetic mixture of ropivacaine 0.375% and lidocaine 1%) and a 100mg dose of oral gabapentin 4 nights daily before surgery and 2 weeks postoperatively.
Study: NCT06426017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Low Calorie Dietary Intervention
Description: High Protein Diet: Diet consisting of 40-60% total energy from proteins, \<20% total energy from carbohydrates and \<30% total energy from fats.
Study: NCT06248398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery with RobOtol®
Description: Patient having cochlear implantation surgery with RobOtol®.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional manual surgery
Description: Patient having conventional manual cochlear implantation surgery
Study: NCT05305209

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: The patients will receive 12 minutes of intravaginal application and 4 minutes of extracavitary application, twice a week for 6 weeks. The difference compared to the intervention of group 1 is that the device will be off and therefore will not emit energy.
Study: NCT05838001

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wire-guided localization and marker clip localization
Description: Positioning guide wire and marker clip in the center of the breast lesion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: marker clip localization
Description: Positioning marker clip in the center of the breast lesion
Study: NCT05130125

Intervention type: DRUG
Intervention: rFSH
Description: rFSH or HP-hMG or rFSH and HP-hMG

Intervention type: DRUG
Intervention: rFSH
Description: rFSH or HP-hMG or rFSH and HP-hMG
Study: NCT04844177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conditioning with TLI
Description: Total lymphoid irradiation 4 Gy (days -7, -6) in combination with:~* Fludarabine 150 mg/m2 (days-6, -5, -4, -3, -2)~* Cyclophosphamide 120 mg/kg (days -5, -4, -3)~* Thymoglogulin (Genzyme) 5 mg/kg (days -5, -4)~* Melphalan 180 mg/m2 (day -2)~* Rituximab 100 mg/m2 (day -1)~* Hematopoietic stem cell graft infusion after TCRab/CD19 depletion - day 0
Study: NCT05786729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AER)
Description: Aerobic exercise will be performed by utilizing aerobic exercise equipment 3 times per week.
Study: NCT05156242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active-tDCS priming MCE
Description: tDCS is used to enhance cortical excitability before motor control exercises.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-tDCS priming MCE
Description: tDCS will be set at 0 mA for 20 minutes before motor control exercise.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NMES priming MCE
Description: NMES is used to enhance lumbar multifidus motor unit recruitment before motor control exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Conventional physical therapy includes modality for pain control, general exercise to improve muscle strength, endurance, and flexibility, and functional training (sit to stand, walking, etc.).
Study: NCT06214897

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C-RUSF (Ready-to-use Supplemental Food with added Choline)
Description: Ready-to-use Supplemental Food with added Choline

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: S-RUSF (Ready-to-use Supplemental Food without added Choline)
Description: Standard Ready-to-use Supplemental Food
Study: NCT04936971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Switch from Mycophenolate Mofetil to Everolimus manteinance treatment in Active Comparator Arm
Description: Switch from Mycophenolate Mofetil in Active comparator Arm if assymptomatic Cytomegalovirus viremia \>1000-\<5000 copies/mL observed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no intervention
Description: Manteinance of assigned Arm treatment even if assymptomatic Cytomegalovirus viremia \>1000-\<5000 copies/mL observed
Study: NCT06498024

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kellogg's - rice krispies (control)
Description: One serving size (140g) of whole white rice cereal will be provided. Preparation will be consistently maintained throughout.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kellogg's - rice krispies (control) + 125ml milk
Description: One serving size (140g) of whole white rice cereal with 125ml of milk will be provided. Preparation will be consistently maintained throughout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel cereal (40% Canadian wild rice, 60% fava bean blend) + 125 ml milk
Description: One serving size (140g) of novel cereal (40% Canadian wild rice, 60% fava bean blend) with 125ml of milk will be provided. Preparation will be consistently maintained throughout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel cereal (40% Canadian wild rice, 60% fava bean blend)
Description: One serving size (140g) of novel cereal (40% Canadian wild rice, 60% fava bean blend) will be provided. Preparation will be consistently maintained throughout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel cereal (40% Canadian wild rice, 50% fava bean blend) + 10% purple powder (sweet potato)
Description: One serving size (140g) of novel cereal (40% Canadian wild rice, 60% fava bean blend) with a 10% added purple powder (sweet potato) will be provided. Preparation will be consistently maintained throughout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel cereal (40% Canadian wild rice, 50% fava bean blend) + 10% purple powder (sweet potato) + 125 ml milk
Description: One serving size (140g) of novel cereal (40% Canadian wild rice, 50% fava bean blend) and 10% purple powder (sweet potato) with 125 ml milk. Preparation will be consistently maintained throughout.
Study: NCT05982236

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire on WEPI software (secure data), with link sent by e-mail to patients included in the study, including PCOSQOL, HADS, FACT G7 et ASEX scores.
Study: NCT05786729

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Rehabilitative program is focused on completion of activities of daily living, initiation, appropriate behavior and community integration for five days per week at the Centre for Neuro Skills.
Study: NCT05224375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Closure
Description: Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure System
Study: NCT05842655

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The wear of screw-retained implant-supported metal-ceramic dental prostheses and natural tooth
Description: A novel digital technique to analyze the wear of screw-retained implant-supported metal-ceramic dental prostheses and natural tooth as antagonist
Study: NCT03608280

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone autograft
Description: The principle of this surgery is based on the removal of a portion of the outer bone layer from the vault of the skull in order to have a flat and solid bone element (cortical bone), which can be carved freehand to better replace the defective bone wall.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orbital reconstruction by 3D-printed porous titanium implant
Description: From data of a patient's CT-scan, it is possible to perform a mirroring. The unaffected orbit is mirrored onto the affected orbit, via a virtual treatment planning, in order to rely on facial symmetry to virtually restore healthy anatomy. From this simulation, the implant is 3D-printed by Selective Laser Melted (SLM) technique using titanium powder. This technique enabling the creation of custom-made implants is called computer-aided design and computer-aided manufacturing (CAD-CAM).~After sterilization, the implant is ready to be placed during a surgical procedure.
Study: NCT04963205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable bed backrest
Description: The adjustable bed backrest facilitates for the individual high lying with a fowler (90 degrees raised head and trunk) and/or semi fowler position (30-45 degrees raised head and trunk) which enables patient's lung expansion. The diaphragm is pulled downwards by the gravity allowing for lung expansion and improved ventilation. In addition, the upper airways are stretched in order to prevent upper airway narrowing during sleep (flow limitation, snoring, obstructive sleep apnea). The position relaxes the tension of the abdominal muscles, allowing for improved breathing. Patients can define their own most comfortable position during the night. Elevated body position over 30 degrees from supine position is a requirement for the intervention group. No sleeping time restrictions will be applied. One week washout period between the interventions will be used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard bed
Description: Sleeping in a standard bed, in a position below 30 degrees from supine position. No sleeping time restrictions will be applied. One week washout period between the interventions will be used.
Study: NCT05703984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC2129A(Period 1)
Description: Linagliptin and Metformin Hydrochloride Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)
Description: Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC2129A(Period 2)
Description: Linagliptin and Metformin Hydrochloride Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)
Description: Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
Study: NCT06246448

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted radical cholecystectomy
Description: Procedure will be performed robotic-assisted

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open radical cholecystectomy
Description: Procedure will be open
Study: NCT05865613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field
Description: Participants were randomized into either the PEMF group or sham treatment group by a computer-generated random number. The participants were treated using PEMF (20 G ,7H for 10min) and sham treatment. treatment was delivered for one month.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Pulsed electromagnetic field
Description: Participants were randomized into either the PEMF group or sham treatment group by a computer-generated random number. The participants were treated using PEMF (20 G ,7H for 10min) and sham treatment. treatment was delivered for one month.
Study: NCT06100315

Intervention type: DRUG
Intervention: Nalbuphine
Description: bupivacaine 0.125% of 0.2 ml/kg and 0.1 mg/kg nalbuphine
Study: NCT06474897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone therapy
Description: Ozone therapy will be practiced to study group. Inject 10 ml of ozone gas (O2-O3) at a concentration of 10 µg/ml 3 times at one week intervals. All injections will be performed by the same experienced specialist doctor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization
Description: Mulligan mobilization will be practiced to control group. Mobilizations will be performed once a week for 3 consecutive weeks. The first one is a seated position with the patient's arm in approximately 90° abduction. The patient will be asked to abduct the arm and at the same time the physiotherapist will perform posterio/lateral gliding of the shoulder head with the left hand.
Study: NCT06409221

Intervention type: OTHER
Intervention: Non-interventional study, Observational only
Description: Observational study only, there are no planned interventions.

Intervention type: OTHER
Intervention: Non-interventional study, Observational only
Description: Observational study only, there are no planned interventions.
Study: NCT06222216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chilled Needle
Description: Before subcutaneous injection, 26G sterile disposable needles will be kept in the refrigerated compartment of the refrigerator for at least 24 hours. Immediately before SC injection, the needle will be removed from the refrigerator, placed in the ice box and placed next to the patient's bed. The needle temperature will be kept at 0-2 degrees Celsius in the ice box and controlled using an LCD digital thermometer. If Enoxaparin Sodium is in the ready injector, the drug in the injector will be drawn into the injector suitable for 1 cc SC injection application without loss of dose. The needle of the prepared syringe will be replaced with a cooled needle. Afterwards, the injection will be made in the designated area (outer side of the upper arm) in accordance with the SC injection procedure steps. After the injection, the patient's pain assessment will be made and marked on the ILC, and ecchymosis assessment will be made after 24, 48 and 72 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: SC injection will be administered to the control group in accordance with the clinical routine. No different action will be applied. The injection will be made in accordance with the SC injection protocol with a needle at room temperature, without applying any tools or procedures. After the injection, the patient's pain will be evaluated and marked on the VAS, and ecchymosis will be evaluated after 24, 48 and 72 hours.
Study: NCT05319106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stem cell preparation combined with silver ion dressing
Description: The dosage range of each cm2 ulcer wound is (1～5)×10\^6. The dosage of human umbilical cord mesenchymal stem cells for the second treatment is determined according to the severity of the ulcer. Each patient is treated for 2 consecutive times, and the interval between each treatment is 3 days.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: silver ion dressing
Description: fter wound debridement, a silver ion dressing suitable for the size of the wound was cut and covered on the wound bed. Sterile gauze was covered on the silver ion dressing and fixed with adhesive tape.
Study: NCT06484270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation based safety mobilization program
Description: Nurse participants experienced safe patient mobilization with a simulation-based learning method with a standardized patient for 4 weeks.~Patient participants were mobilized safely under the supervision of a nurse and the care results were measured.
Study: NCT06016010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USL
Description: 500mg of Achyranthis Radix Extract

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USL
Description: 500mg of Achyranthis Radix Extract

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: USL Placebo
Description: USL Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USL Placebo
Description: USL Placebo
Study: NCT05908214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wide pulse high frequency neuromuscular electrical stimulation training
Description: Plantar flexors will be stimulated with wide pulse high frequency neuromuscular electrical stimulation 3 times a week for 6 weeks